Nutriband Inc
NTRB4.350USD
+0.070+1.64%
終値 02/06, 16:00（ET）15分遅れの株価
52.88M時価総額
損失額直近12ヶ月PER
詳細情報 Nutriband Inc 企業名
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Nutriband Incの企業情報
企業コードNTRB
会社名Nutriband Inc
上場日Jun 20, 2017
最高経営責任者「CEO」Melnik (Serguei)
従業員数- -
証券種類Ordinary Share
決算期末Jun 20
本社所在地121 S Orange Ave Ste 1500
都市ORLANDO
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号32801-3241
電話番号14073776695
ウェブサイトhttps://nutriband.com/
企業コードNTRB
上場日Jun 20, 2017
最高経営責任者「CEO」Melnik (Serguei)
Nutriband Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
939.42K
+119000.00%
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
13.96K
-3249.00%
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
1.17K
--
Dr. Alan Smith, Ph.D.
Dr. Alan Smith, Ph.D.
Chief Operating Officer, President of 4P Therapeutics
Chief Operating Officer, President of 4P Therapeutics
--
--
Prof. Dr. Stefani C. Mancas
Prof. Dr. Stefani C. Mancas
Independent Director
Independent Director
--
--
Mr. Sergei Glinka
Mr. Sergei Glinka
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
939.42K
+119000.00%
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
13.96K
-3249.00%
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
1.17K
--
収益内訳
通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2026Q3
FY2026Q2
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Sale of goods
346.06K
0.00%
Services
0.00
0.00%
地域別USD
会社名
収益
比率
United States
346.06K
100.00%
Non-United States
0.00
0.00%
事業別
地域別
事業別USD
会社名
収益
比率
Sale of goods
346.06K
0.00%
Services
0.00
0.00%
株主
更新時刻: Sat, Jan 31
更新時刻: Sat, Jan 31
株主統計
種類
株主統計
株主統計
比率
Botgros (Vitalie)
26.44%
TII Jet Services, LDA
14.85%
Sheridan (Gareth)
14.47%
Glinka (Serguei)
9.19%
Melnik (Serguei)
7.72%
他の
27.33%
株主統計
株主統計
比率
Botgros (Vitalie)
26.44%
TII Jet Services, LDA
14.85%
Sheridan (Gareth)
14.47%
Glinka (Serguei)
9.19%
Melnik (Serguei)
7.72%
他の
27.33%
種類
株主統計
比率
Individual Investor
59.53%
Corporation
14.85%
Investment Advisor
2.06%
Investment Advisor/Hedge Fund
0.82%
Research Firm
0.04%
他の
22.70%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
40
355.48K
2.92%
-101.91K
2025Q3
36
350.65K
2.91%
-71.29K
2025Q2
44
8.87M
79.52%
+489.89K
2025Q1
43
8.13M
73.14%
+1.78M
2024Q4
40
8.04M
72.39%
+1.68M
2024Q3
40
8.08M
72.79%
+1.82M
2024Q2
38
5.19M
52.25%
+2.18M
2024Q1
34
4.36M
55.65%
+1.38M
2023Q4
30
4.30M
54.90%
+1.31M
2023Q3
29
2.96M
37.78%
-39.44K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Botgros (Vitalie)
3.22M
26.44%
+132.25K
+4.28%
Dec 17, 2025
TII Jet Services, LDA
1.81M
14.85%
+485.05K
+36.66%
Sep 01, 2024
Sheridan (Gareth)
1.76M
14.47%
--
--
Dec 17, 2025
Glinka (Serguei)
1.12M
9.19%
+294.04K
+35.64%
Dec 17, 2025
Melnik (Serguei)
939.42K
7.72%
+119.00K
+14.50%
Dec 17, 2025
The Vanguard Group, Inc.
202.74K
1.67%
+3.11K
+1.56%
Sep 30, 2025
Goodman (Gerald)
86.33K
0.71%
--
--
Dec 17, 2025
Geode Capital Management, L.L.C.
59.94K
0.49%
-3.69K
-5.80%
Sep 30, 2025
Smith (Allan)
36.91K
0.3%
-5.00K
-11.93%
Dec 17, 2025
Patrick (Jeff)
36.61K
0.3%
--
--
Dec 17, 2025
詳細を見る
関連ETF
更新時刻: Tue, Dec 2
更新時刻: Tue, Dec 2
銘柄名
比率
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
Jul 29, 2022
Split
6→7
日付
配当落ち日
種類
比率
Jul 29, 2022
Split
6→7
